...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: 47 Taken out by Gilead for $4.9 billion

They are in oncology where the highest selling most profitable drugs are. FTSV could have their drug right up there in combination with PD-1s.  They had positive trial results, we had a failed PH3.  I agree there is potential here but until we get financing figured out you guys are expecting too much.  

Share
New Message
Please login to post a reply